HK2 and hepatocellular carcinoma: Specifically, hexokinase 2 (HK2) upregulation in hepatocellular carcinoma and glioblastoma results from promoter hypomethylation, favoring glycolytic flux (Goel et al., 2003; Wolf et al., 2011).